Treatment of bipolar depression: making sensible decisions.

Abstract

A major challenge in the treatment of major depressive episodes associated with bipolar disorder is differentiating this illness from major depressive episodes associated with major depressive disorder. Mistaking the former for the latter will lead to incorrect treatment and poor outcomes. None of the classic antidepressants, serotonin specific reuptake inhibitors, or serotonin-norepinephrine reuptake inhibitors have ever received regulatory approval as monotherapies for the treatment of bipolar depression. At present, there are only 3 approved medication treatments for bipolar depression: olanzapine/fluoxetine combination, quetiapine (immediate or extended release), and lurasidone (monotherapy or adjunctive to lithium or valproate). All 3 have similar efficacy profiles, but they differ in terms of tolerability. Number needed to treat (NNT) and number needed to harm (NNH) can be used to quantify these similarities and differences. The NNTs for response and remission for each of these interventions vs placebo range from 4 to 7, and 5 to 7, respectively, with overlap in terms of their 95% confidence intervals. NNH values less than 10 (vs placebo) were observed for the spontaneously reported adverse events of weight gain and diarrhea for olanzapine/fluoxetine combination (7 and 9, respectively) and somnolence and dry mouth for quetiapine (3 and 4, respectively). There were no NNH values less than 10 (vs placebo) observed with lurasidone treatment. NNH values vs placebo for weight gain of at least 7% from baseline were 6, 16, 58, and 36, for olanzapine/fluoxetine combination, quetiapine, lurasidone monotherapy, and lurasidone combined with lithium or valproate, respectively. Individualizing treatment decisions will require consideration of the different potential adverse events that are more likely to occur with each medication. The metric of the likelihood to be helped or harmed (LHH) is the ratio of NNH to NNT and can illustrate the tradeoffs inherent in selecting medications. A more favorable LHH was noted for treatment with lurasidone. However, OFC and quetiapine monotherapy may still have utility in high urgency situations, particularly in persons who have demonstrated good outcomes with these interventions in the past, and where a pressing clinical need for efficacy mitigates their potential tolerability shortcomings. In terms of maintenance therapy, adjunctive quetiapine is the only agent where the NNT vs lithium or valproate alone is less than 10 for both the prevention of mania and the prevention of depression.

• Authors: Leslie Citrome
• Journal: CNS spectrums (CNS Spectr) Vol. 19 Suppl 1 Pg. 4-11; quiz 1-3, 12 (Dec 2014) ISSN: 1092-8529 [Print] United States
• PMID: 25407667 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antidepressive Agents
• Antimanic Agents
• Antipsychotic Agents
• Dibenzothiazepines
• Drug Combinations
• Isoindoles
• Lithium Compounds
• Thiazoles
• olanzapine-fluoxetine combination
• Fluoxetine
• Benzodiazepines
• Quetiapine Fumarate
• Valproic Acid
• Lurasidone Hydrochloride

Topics

• Antidepressive Agents (therapeutic use)
• Antimanic Agents (therapeutic use)
• Antipsychotic Agents (therapeutic use)
• Benzodiazepines (therapeutic use)
• Bipolar Disorder (drug therapy)
• Depressive Disorder, Major (drug therapy)
• Dibenzothiazepines (therapeutic use)
• Drug Combinations
• Drug Therapy, Combination
• Fluoxetine (therapeutic use)
• Humans
• Isoindoles (therapeutic use)
• Lithium Compounds (therapeutic use)
• Lurasidone Hydrochloride
• Quetiapine Fumarate
• Thiazoles (therapeutic use)
• Valproic Acid (therapeutic use)